Targeted Radionuclide Therapy Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Targeted Radionuclide Therapy market size was valued at USD 1073.2 million in 2022 and is forecast to a readjusted size of USD 3154.4 million by 2029 with a CAGR of 16.7% during review period.

Therapeutic Radioligands is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.

The key drivers of the radioimmunotherapy market is its potential to deliver highly targeted and precise treatment to cancer cells, sparing healthy tissues and reducing side effects compared to traditional radiation therapies. The ability of RIT to offer personalized treatment options based on specific cancer biomarkers further enhances its appeal in the field of precision medicine. However, the radioimmunotherapy market also faces challenges. One major challenge is the high cost associated with the development and production of radiopharmaceuticals, limiting access for some patients and healthcare systems. Additionally, navigating complex regulatory pathways for approval and reimbursement of RIT products can be time-consuming and resource-intensive for pharmaceutical companies. Furthermore, there may be limited awareness and acceptance of RIT among healthcare professionals and patients, leading to slower adoption rates and market penetration. Addressing these challenges requires continued research and investment in RIT technologies to improve efficacy and cost-effectiveness. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate knowledge-sharing and streamline the regulatory process.

Report includes an overview of the development of the Targeted Radionuclide Therapy industry chain, the market status of Solid Tumor (Beta-emitting, Targeted Alpha Therapy), Non Hodgkin Lymphoma (Beta-emitting, Targeted Alpha Therapy), and key enterprises in developed and developing market, and analyzed the cutting-edge technology, patent, hot applications and market trends of Targeted Radionuclide Therapy.

Regionally, the report analyzes the Targeted Radionuclide Therapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Targeted Radionuclide Therapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Targeted Radionuclide Therapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Targeted Radionuclide Therapy industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Beta-emitting, Targeted Alpha Therapy).

Industry Analysis: Report analyze the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Targeted Radionuclide Therapy market.

Regional Analysis: The report involves examining the Targeted Radionuclide Therapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behavior to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Targeted Radionuclide Therapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Targeted Radionuclide Therapy:

Company Analysis: Report covers individual Targeted Radionuclide Therapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behavior, preferences, and attitudes towards Targeted Radionuclide Therapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Solid Tumor, Non Hodgkin Lymphoma).

Technology Analysis: Report covers specific technologies relevant to Targeted Radionuclide Therapy. It assesses the current state, advancements, and potential future developments in Targeted Radionuclide Therapy areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Targeted Radionuclide Therapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

   Bayer
   Novartis
   Lantheus
   Aurobindo Pharma
   Mundipharma
   China Isotope & Radiation
   Curium Pharmaceuticals
   Gilead Sciences
   Clarity Pharmaceuticals
   Curasight
   Nordic Nanovector
   Philogen
   RadioMedix
   Telix Pharmaceuticals
   Orano Med
   Actinium Pharmaceuticals
   Y-mAbs Therapeutics
   Fusion Pharmaceuticals

   Beta-emitting
   Targeted Alpha Therapy

   Solid Tumor
   Non Hodgkin Lymphoma

   North America (United States, Canada, and Mexico)
   Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
   South America (Brazil, Argentina and Rest of South America)
   Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

What are the strengths of the Targeted Radionuclide Therapy market in 2025?

The Targeted Radionuclide Therapy market in 2025 will benefit from advanced precision in treatment, allowing for localized targeting of cancer cells, minimizing damage to healthy tissue. The increasing prevalence of cancer, especially in aging populations, and the rising demand for personalized medicine are key strengths. Moreover, growing investments in research and development are likely to enhance therapeutic outcomes.

What are the weaknesses in the Targeted Radionuclide Therapy market in 2025?

The primary weakness is the high cost associated with radionuclide therapies, making it less accessible in certain regions, especially in developing countries. There are also challenges related to the availability of radionuclides, which may be limited by production capabilities and regulatory hurdles. Additionally, the side effects of radiation and limited long-term data on the efficacy of these treatments may hinder broader adoption.

What opportunities exist in the Targeted Radionuclide Therapy market in 2025?

With increasing awareness of advanced cancer treatments and rising government and private sector investments, there is significant opportunity for growth. The integration of artificial intelligence and imaging technologies can enhance the precision of radionuclide delivery. New treatment indications beyond cancer, such as in autoimmune diseases, could further expand market opportunities. Additionally, collaborations between pharmaceutical companies and research institutions may drive innovation.

What are the threats to the Targeted Radionuclide Therapy market in 2025?

The main threats include stringent regulatory processes that could delay the approval of new therapies. There is also the risk of competition from alternative treatment options, such as immunotherapies and targeted therapies, which might overshadow radionuclide therapy. Public concerns about the safety of radiation and potential side effects may impact patient acceptance, further restricting market growth.

What are the political factors influencing the Targeted Radionuclide Therapy market in 2025?

Political stability and government healthcare policies will greatly impact the growth of the Targeted Radionuclide Therapy market. National and international regulations around the use of radioactive materials can affect the approval and distribution of therapies. Additionally, healthcare reforms and reimbursement policies will determine the accessibility of these therapies for patients, particularly in developed regions.

How do economic factors affect the Targeted Radionuclide Therapy market in 2025?

Economic conditions, including healthcare funding and the overall economic climate, will influence market expansion. The high cost of targeted radionuclide therapies may limit their adoption, especially in price-sensitive regions. Economic downturns or insufficient reimbursement from healthcare systems could slow market growth. However, economic growth in emerging markets presents an opportunity for expanding access to these advanced therapies.

What are the social factors affecting the Targeted Radionuclide Therapy market in 2025?

As awareness and demand for more personalized medicine increase, patients will likely seek targeted therapies for cancer treatment, driving market growth. The aging population and the rising prevalence of cancer worldwide will also create a significant demand for these therapies. Social attitudes toward radiation and the willingness to adopt new treatments may impact patient acceptance and market penetration.

How do technological factors impact the Targeted Radionuclide Therapy market in 2025?

Advancements in medical imaging, artificial intelligence, and radiopharmaceutical development will significantly improve the precision and efficacy of targeted radionuclide therapies. Cutting-edge technologies for radionuclide production and improved radiation delivery mechanisms will enhance treatment outcomes, driving adoption. However, the technology’s complexity and the need for specialized infrastructure could pose challenges to widespread use.

What environmental factors influence the Targeted Radionuclide Therapy market in 2025?

Environmental regulations around the disposal of radioactive materials and the sustainable production of radionuclides will play a crucial role in shaping the market. Additionally, eco-friendly practices in manufacturing and transportation of radiopharmaceuticals may become more important due to increasing environmental concerns. These factors could influence production costs and the availability of raw materials for therapy.

What legal factors impact the Targeted Radionuclide Therapy market in 2025?

Strict regulations regarding the approval and use of radionuclide-based treatments, as well as intellectual property laws surrounding new radiopharmaceuticals, will impact the market. Legal challenges may arise from patient safety concerns, and any legal disputes or patent issues could delay the introduction of new therapies. Compliance with international standards for radiation safety and therapy delivery will also be key to market growth.

Who are the suppliers in the Targeted Radionuclide Therapy market in 2025?

The suppliers include companies involved in the production of radiopharmaceuticals, medical imaging technologies, and radionuclides. Key players in the supply chain are manufacturers of radioisotopes, equipment producers for precision delivery systems, and biotech companies focused on therapy development. Additionally, research institutions and universities may also supply critical data and innovations in this field.

What inputs are required for the Targeted Radionuclide Therapy market in 2025?

The inputs required include high-quality radionuclides, medical imaging systems for precision targeting, radiation therapy devices, and specialized infrastructure for radiopharmaceutical production. Skilled medical professionals and advanced software for patient diagnostics and therapy planning are also key inputs. Regulatory approvals and financial investment in R&D are essential for further development.

Who are the process owners in the Targeted Radionuclide Therapy market in 2025?

The process owners in this market are pharmaceutical companies, healthcare providers, medical institutions, and regulatory bodies. Pharmaceutical companies lead the development and manufacturing of radiopharmaceuticals, while hospitals and clinics are responsible for administering therapies. Regulatory bodies, such as health authorities, ensure compliance and safety standards in the treatment process.

Who are the customers in the Targeted Radionuclide Therapy market in 2025?

The primary customers are cancer patients, particularly those with specific types of tumors that can benefit from targeted radiation therapy. Healthcare providers, including hospitals, oncology clinics, and research institutions, are secondary customers that purchase therapies and equipment. Insurance companies also play a role by reimbursing the cost of treatment for patients in certain markets.

What are the outcomes expected from the Targeted Radionuclide Therapy market in 2025?

The expected outcomes include improved therapeutic efficacy with minimal side effects, enhanced survival rates for patients, and better quality of life for those undergoing cancer treatment. Additionally, there will be a growing shift toward personalized treatment plans, with more patients gaining access to precision-targeted therapies. Advancements in research will likely lead to new applications for these therapies, expanding their use beyond oncology.

What is the threat of new entrants in the Targeted Radionuclide Therapy market in 2025?

The threat of new entrants is moderate to low due to high barriers to entry. The development of radionuclide therapies requires significant investment in research, infrastructure, and regulatory approval. Additionally, the complex nature of radionuclide production and the need for specialized technology and expertise limit the number of new players. However, increasing market demand and technological advancements could still attract new companies.

What is the bargaining power of suppliers in the Targeted Radionuclide Therapy market in 2025?

The bargaining power of suppliers is moderate to high. The production of radionuclides and radiopharmaceuticals is concentrated among a few specialized companies, giving these suppliers significant power. Additionally, the complexity of sourcing and producing radioactive materials, as well as regulatory constraints, can make it difficult to switch suppliers. However, advancements in technology may eventually reduce supplier power by increasing supply options.

What is the bargaining power of buyers in the Targeted Radionuclide Therapy market in 2025?

The bargaining power of buyers is moderate. While individual patients have limited bargaining power, healthcare providers and insurers, who make purchasing decisions on behalf of patients, can influence pricing and availability. As the market expands and new therapies emerge, buyers may have more options, which could increase their bargaining power. However, the high cost and specialized nature of these treatments limit buyer influence.

What is the threat of substitute products or services in the Targeted Radionuclide Therapy market in 2025?

The threat of substitutes is moderate. While alternative cancer treatments like chemotherapy, immunotherapy, and targeted therapy exist, they are not direct substitutes for radionuclide therapy in terms of precision and localized treatment. However, ongoing advancements in other treatment modalities could offer more effective or less invasive alternatives, which may reduce the demand for radionuclide therapies in certain applications.

What is the intensity of competitive rivalry in the Targeted Radionuclide Therapy market in 2025?

The intensity of competitive rivalry is moderate. The market is driven by a few key players, including major pharmaceutical companies and specialized radiopharmaceutical firms, which compete on the basis of technological innovation, treatment efficacy, and regulatory approvals. As the market grows and more players enter, the competition will likely intensify, but the specialized nature of the field and regulatory hurdles will limit the number of direct competitors.

What are the key raw materials required in the Targeted Radionuclide Therapy market in 2025?

The key raw materials include radioisotopes such as lutetium-177, iodine-131, and yttrium-90, which are essential for the production of radiopharmaceuticals. Other materials include specialized chemicals for radiolabeling, as well as high-purity solvents and stabilizers. The production of medical imaging agents and other compounds for therapy delivery also requires specific chemicals and reagents.

What are the major suppliers and manufacturers in the upstream of the Targeted Radionuclide Therapy market?

The major suppliers in the upstream include companies that specialize in the production of radionuclides, such as cyclotron facilities and nuclear reactors. Additionally, manufacturers of radiopharmaceuticals and medical devices for treatment delivery, like radiation delivery systems, are critical. These suppliers often work with research institutions and universities to develop new compounds and delivery mechanisms.

What technologies are driving the upstream activities in the Targeted Radionuclide Therapy market in 2025?

Key technologies include advancements in cyclotron technology for producing radionuclides, radiolabeling techniques for attaching isotopes to targeting molecules, and innovations in imaging technologies that guide precise delivery. The development of automated production systems for radiopharmaceuticals, as well as advances in nuclear medicine, are improving efficiency and reducing the time to deliver therapies.

What regulatory challenges impact the upstream sector of the Targeted Radionuclide Therapy market?

Regulatory challenges include strict guidelines for the production, handling, and transportation of radioactive materials. Compliance with radiation safety regulations is essential, as well as ensuring the quality control of radiopharmaceuticals. Additionally, gaining approval from regulatory bodies such as the FDA or EMA can be a lengthy process, which may impact the timely availability of materials required for targeted therapy.

What are the economic pressures faced by upstream suppliers in the Targeted Radionuclide Therapy market?

Upstream suppliers face significant economic pressures related to the high cost of producing radioactive isotopes and maintaining specialized facilities for their production. The volatility in raw material prices, such as the cost of rare isotopes, and the need for continuous investment in advanced technology, also put pressure on margins. Additionally, regulatory compliance and safety measures add to operational costs.

What are the key processes in the midstream of the Targeted Radionuclide Therapy market in 2025?

The key processes include the manufacturing, formulation, and packaging of radiopharmaceuticals, followed by their distribution to healthcare facilities. This also involves the quality control and validation of therapies, ensuring that each batch meets regulatory and safety standards. Additionally, logistics related to the safe transportation of radioactive materials are critical at this stage.

What are the major players in the midstream of the Targeted Radionuclide Therapy market?

Major players in the midstream include radiopharmaceutical manufacturers, contract manufacturing organizations (CMOs), and specialized distributors of radiopharmaceuticals. Companies that specialize in the production and distribution of isotopes, as well as those involved in packaging and handling radioactive materials, play a significant role in ensuring the supply chain functions smoothly.

What technologies are critical to the midstream of the Targeted Radionuclide Therapy market?

Key technologies include advanced radiolabeling techniques, automated production systems for consistency, and radiation safety technologies that ensure safe handling and packaging. Logistics management systems that allow for the tracking and safe transportation of radiopharmaceuticals are also critical. Furthermore, innovations in cold chain management are essential to maintain the efficacy and safety of radioactive therapies during transport.

What regulatory and quality control challenges impact the midstream sector of the Targeted Radionuclide Therapy market?

Regulatory challenges include ensuring compliance with strict safety protocols for handling and transporting radioactive materials, as well as maintaining Good Manufacturing Practices (GMP). Quality control is vital to ensure that radiopharmaceuticals meet stringent standards for purity, potency, and safety. Additionally, the approval process for new products can slow the availability of therapies in the market.

What economic factors affect the midstream sector of the Targeted Radionuclide Therapy market?

Economic factors affecting the midstream include the cost of specialized production equipment, compliance with regulatory standards, and the rising costs of transportation due to the need for secure and temperature-controlled logistics. Fluctuations in the price of raw materials, such as radionuclides, and the costs associated with maintaining state-of-the-art manufacturing and safety protocols also have an impact.

What are the key activities in the downstream of the Targeted Radionuclide Therapy market in 2025?

The key activities include the administration of radionuclide therapies in healthcare settings, such as hospitals and oncology clinics. This also involves patient monitoring, post-treatment care, and follow-up assessments to evaluate treatment efficacy and side effects. Additionally, physicians and healthcare providers are critical in developing personalized treatment plans for patients based on imaging and diagnostic results.

Who are the major players in the downstream sector of the Targeted Radionuclide Therapy market?

Major players in the downstream sector include healthcare providers like hospitals, oncology centers, and specialized clinics that deliver targeted radionuclide therapies. Physicians, nuclear medicine specialists, and radiation oncologists are also vital players in the administration and oversight of the therapies. Insurance companies are also part of the downstream ecosystem as they determine reimbursement policies for patients undergoing these treatments.

What technologies are important for the downstream activities in the Targeted Radionuclide Therapy market?

Technologies critical for downstream activities include advanced imaging systems like PET and SPECT scans, which help in the precise targeting and monitoring of radionuclide therapies. Additionally, radiation therapy equipment and patient management systems play key roles in treatment delivery and follow-up care. Telemedicine and AI-powered diagnostics may also improve patient monitoring and treatment personalization.

What regulatory and safety challenges affect the downstream sector of the Targeted Radionuclide Therapy market?

Regulatory challenges include ensuring that the delivery of radionuclide therapies adheres to safety standards, particularly regarding radiation exposure to both patients and healthcare providers. There are also strict protocols for patient consent, ethical treatment practices, and the safe disposal of radioactive waste. Additionally, reimbursement policies and regulatory approvals for new therapies can influence the availability and affordability of treatments.

What economic factors impact the downstream sector of the Targeted Radionuclide Therapy market?

Economic factors influencing the downstream sector include the cost of therapy and the ability of healthcare systems and patients to afford these treatments. Reimbursement rates from insurance companies and government healthcare programs directly impact patient access. Economic pressures, such as healthcare budget constraints or cost-cutting measures in hospitals, may affect the adoption and availability of these advanced therapies.

Chapter 1, to describe Targeted Radionuclide Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Targeted Radionuclide Therapy, with revenue, gross margin and global market share of Targeted Radionuclide Therapy from 2018 to 2023.
Chapter 3, the Targeted Radionuclide Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Targeted Radionuclide Therapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted Radionuclide Therapy.
Chapter 13, to describe Targeted Radionuclide Therapy research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Targeted Radionuclide Therapy
   1.2 Market Estimation Caveats and Base Year
   1.3 Classification of Targeted Radionuclide Therapy by Type
       1.3.1 Overview: Global Targeted Radionuclide Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Global Targeted Radionuclide Therapy Consumption Value Market Share by Type in 2022
       1.3.3 Beta-emitting
       1.3.4 Targeted Alpha Therapy
   1.4 Global Targeted Radionuclide Therapy Market by Application
       1.4.1 Overview: Global Targeted Radionuclide Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Solid Tumor
       1.4.3 Non Hodgkin Lymphoma
   1.5 Global Targeted Radionuclide Therapy Market Size & Forecast
   1.6 Global Targeted Radionuclide Therapy Market Size and Forecast by Region
       1.6.1 Global Targeted Radionuclide Therapy Market Size by Region: 2018 VS 2022 VS 2029
       1.6.2 Global Targeted Radionuclide Therapy Market Size by Region, (2018-2029)
       1.6.3 North America Targeted Radionuclide Therapy Market Size and Prospect (2018-2029)
       1.6.4 Europe Targeted Radionuclide Therapy Market Size and Prospect (2018-2029)
       1.6.5 Asia-Pacific Targeted Radionuclide Therapy Market Size and Prospect (2018-2029)
       1.6.6 South America Targeted Radionuclide Therapy Market Size and Prospect (2018-2029)
       1.6.7 Middle East and Africa Targeted Radionuclide Therapy Market Size and Prospect (2018-2029)

2 Company Profiles

   2.1 Bayer
       2.1.1 Bayer Details
       2.1.2 Bayer Major Business
       2.1.3 Bayer Targeted Radionuclide Therapy Product and Solutions
       2.1.4 Bayer Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Bayer Recent Developments and Future Plans
   2.2 Novartis
       2.2.1 Novartis Details
       2.2.2 Novartis Major Business
       2.2.3 Novartis Targeted Radionuclide Therapy Product and Solutions
       2.2.4 Novartis Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Novartis Recent Developments and Future Plans
   2.3 Lantheus
       2.3.1 Lantheus Details
       2.3.2 Lantheus Major Business
       2.3.3 Lantheus Targeted Radionuclide Therapy Product and Solutions
       2.3.4 Lantheus Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Lantheus Recent Developments and Future Plans
   2.4 Aurobindo Pharma
       2.4.1 Aurobindo Pharma Details
       2.4.2 Aurobindo Pharma Major Business
       2.4.3 Aurobindo Pharma Targeted Radionuclide Therapy Product and Solutions
       2.4.4 Aurobindo Pharma Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Aurobindo Pharma Recent Developments and Future Plans
   2.5 Mundipharma
       2.5.1 Mundipharma Details
       2.5.2 Mundipharma Major Business
       2.5.3 Mundipharma Targeted Radionuclide Therapy Product and Solutions
       2.5.4 Mundipharma Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Mundipharma Recent Developments and Future Plans
   2.6 China Isotope & Radiation
       2.6.1 China Isotope & Radiation Details
       2.6.2 China Isotope & Radiation Major Business
       2.6.3 China Isotope & Radiation Targeted Radionuclide Therapy Product and Solutions
       2.6.4 China Isotope & Radiation Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 China Isotope & Radiation Recent Developments and Future Plans
   2.7 Curium Pharmaceuticals
       2.7.1 Curium Pharmaceuticals Details
       2.7.2 Curium Pharmaceuticals Major Business
       2.7.3 Curium Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
       2.7.4 Curium Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Curium Pharmaceuticals Recent Developments and Future Plans
   2.8 Gilead Sciences
       2.8.1 Gilead Sciences Details
       2.8.2 Gilead Sciences Major Business
       2.8.3 Gilead Sciences Targeted Radionuclide Therapy Product and Solutions
       2.8.4 Gilead Sciences Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 Gilead Sciences Recent Developments and Future Plans
   2.9 Clarity Pharmaceuticals
       2.9.1 Clarity Pharmaceuticals Details
       2.9.2 Clarity Pharmaceuticals Major Business
       2.9.3 Clarity Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
       2.9.4 Clarity Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.9.5 Clarity Pharmaceuticals Recent Developments and Future Plans
   2.10 Curasight 
       2.10.1 Curasight Details
       2.10.2 Curasight Major Business
       2.10.3 Curasight Targeted Radionuclide Therapy Product and Solutions
       2.10.4 Curasight Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.10.5 Curasight Recent Developments and Future Plans
   2.11 Nordic Nanovector
       2.11.1 Nordic Nanovector Details
       2.11.2 Nordic Nanovector Major Business
       2.11.3 Nordic Nanovector Targeted Radionuclide Therapy Product and Solutions
       2.11.4 Nordic Nanovector Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.11.5 Nordic Nanovector Recent Developments and Future Plans
   2.12 Philogen
       2.12.1 Philogen Details
       2.12.2 Philogen Major Business
       2.12.3 Philogen Targeted Radionuclide Therapy Product and Solutions
       2.12.4 Philogen Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.12.5 Philogen Recent Developments and Future Plans
   2.13 RadioMedix
       2.13.1 RadioMedix Details
       2.13.2 RadioMedix Major Business
       2.13.3 RadioMedix Targeted Radionuclide Therapy Product and Solutions
       2.13.4 RadioMedix Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.13.5 RadioMedix Recent Developments and Future Plans
   2.14 Telix Pharmaceuticals
       2.14.1 Telix Pharmaceuticals Details
       2.14.2 Telix Pharmaceuticals Major Business
       2.14.3 Telix Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
       2.14.4 Telix Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.14.5 Telix Pharmaceuticals Recent Developments and Future Plans
   2.15 Orano Med
       2.15.1 Orano Med Details
       2.15.2 Orano Med Major Business
       2.15.3 Orano Med Targeted Radionuclide Therapy Product and Solutions
       2.15.4 Orano Med Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.15.5 Orano Med Recent Developments and Future Plans
   2.16 Actinium Pharmaceuticals
       2.16.1 Actinium Pharmaceuticals Details
       2.16.2 Actinium Pharmaceuticals Major Business
       2.16.3 Actinium Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
       2.16.4 Actinium Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.16.5 Actinium Pharmaceuticals Recent Developments and Future Plans
   2.17 Y-mAbs Therapeutics
       2.17.1 Y-mAbs Therapeutics Details
       2.17.2 Y-mAbs Therapeutics Major Business
       2.17.3 Y-mAbs Therapeutics Targeted Radionuclide Therapy Product and Solutions
       2.17.4 Y-mAbs Therapeutics Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.17.5 Y-mAbs Therapeutics Recent Developments and Future Plans
   2.18 Fusion Pharmaceuticals
       2.18.1 Fusion Pharmaceuticals Details
       2.18.2 Fusion Pharmaceuticals Major Business
       2.18.3 Fusion Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
       2.18.4 Fusion Pharmaceuticals Targeted Radionuclide Therapy Revenue, Gross Margin and Market Share (2018-2023)
       2.18.5 Fusion Pharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

   3.1 Global Targeted Radionuclide Therapy Revenue and Share by Players (2018-2023)
   3.2 Market Share Analysis (2022)
       3.2.1 Market Share of Targeted Radionuclide Therapy by Company Revenue
       3.2.2 Top 3 Targeted Radionuclide Therapy Players Market Share in 2022
       3.2.3 Top 6 Targeted Radionuclide Therapy Players Market Share in 2022
   3.3 Targeted Radionuclide Therapy Market: Overall Company Footprint Analysis
       3.3.1 Targeted Radionuclide Therapy Market: Region Footprint
       3.3.2 Targeted Radionuclide Therapy Market: Company Product Type Footprint
       3.3.3 Targeted Radionuclide Therapy Market: Company Product Application Footprint
   3.4 New Market Entrants and Barriers to Market Entry
   3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

   4.1 Global Targeted Radionuclide Therapy Consumption Value and Market Share by Type (2018-2023)
   4.2 Global Targeted Radionuclide Therapy Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

   5.1 Global Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2023)
   5.2 Global Targeted Radionuclide Therapy Market Forecast by Application (2024-2029)

6 North America

   6.1 North America Targeted Radionuclide Therapy Consumption Value by Type (2018-2029)
   6.2 North America Targeted Radionuclide Therapy Consumption Value by Application (2018-2029)
   6.3 North America Targeted Radionuclide Therapy Market Size by Country
       6.3.1 North America Targeted Radionuclide Therapy Consumption Value by Country (2018-2029)
       6.3.2 United States Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       6.3.3 Canada Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       6.3.4 Mexico Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)

7 Europe

   7.1 Europe Targeted Radionuclide Therapy Consumption Value by Type (2018-2029)
   7.2 Europe Targeted Radionuclide Therapy Consumption Value by Application (2018-2029)
   7.3 Europe Targeted Radionuclide Therapy Market Size by Country
       7.3.1 Europe Targeted Radionuclide Therapy Consumption Value by Country (2018-2029)
       7.3.2 Germany Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       7.3.3 France Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       7.3.4 United Kingdom Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       7.3.5 Russia Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       7.3.6 Italy Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)

8 Asia-Pacific

   8.1 Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Type (2018-2029)
   8.2 Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Application (2018-2029)
   8.3 Asia-Pacific Targeted Radionuclide Therapy Market Size by Region
       8.3.1 Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Region (2018-2029)
       8.3.2 China Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       8.3.3 Japan Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       8.3.4 South Korea Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       8.3.5 India Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       8.3.6 Southeast Asia Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       8.3.7 Australia Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)

9 South America

   9.1 South America Targeted Radionuclide Therapy Consumption Value by Type (2018-2029)
   9.2 South America Targeted Radionuclide Therapy Consumption Value by Application (2018-2029)
   9.3 South America Targeted Radionuclide Therapy Market Size by Country
       9.3.1 South America Targeted Radionuclide Therapy Consumption Value by Country (2018-2029)
       9.3.2 Brazil Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       9.3.3 Argentina Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)

10 Middle East & Africa

   10.1 Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Type (2018-2029)
   10.2 Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Application (2018-2029)
   10.3 Middle East & Africa Targeted Radionuclide Therapy Market Size by Country
       10.3.1 Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Country (2018-2029)
       10.3.2 Turkey Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       10.3.3 Saudi Arabia Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)
       10.3.4 UAE Targeted Radionuclide Therapy Market Size and Forecast (2018-2029)

11 Market Dynamics

   11.1 Targeted Radionuclide Therapy Market Drivers
   11.2 Targeted Radionuclide Therapy Market Restraints
   11.3 Targeted Radionuclide Therapy Trends Analysis
   11.4 Porters Five Forces Analysis
       11.4.1 Threat of New Entrants
       11.4.2 Bargaining Power of Suppliers
       11.4.3 Bargaining Power of Buyers
       11.4.4 Threat of Substitutes
       11.4.5 Competitive Rivalry

12 Industry Chain Analysis

   12.1 Targeted Radionuclide Therapy Industry Chain
   12.2 Targeted Radionuclide Therapy Upstream Analysis
   12.3 Targeted Radionuclide Therapy Midstream Analysis
   12.4 Targeted Radionuclide Therapy Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

   14.1 Methodology
   14.2 Research Process and Data Source
   14.3 Disclaimer

List of Tables

   Table 1. Global Targeted Radionuclide Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Targeted Radionuclide Therapy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Global Targeted Radionuclide Therapy Consumption Value by Region (2018-2023) & (USD Million)
   Table 4. Global Targeted Radionuclide Therapy Consumption Value by Region (2024-2029) & (USD Million)
   Table 5. Bayer Company Information, Head Office, and Major Competitors
   Table 6. Bayer Major Business
   Table 7. Bayer Targeted Radionuclide Therapy Product and Solutions
   Table 8. Bayer Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 9. Bayer Recent Developments and Future Plans
   Table 10. Novartis Company Information, Head Office, and Major Competitors
   Table 11. Novartis Major Business
   Table 12. Novartis Targeted Radionuclide Therapy Product and Solutions
   Table 13. Novartis Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 14. Novartis Recent Developments and Future Plans
   Table 15. Lantheus Company Information, Head Office, and Major Competitors
   Table 16. Lantheus Major Business
   Table 17. Lantheus Targeted Radionuclide Therapy Product and Solutions
   Table 18. Lantheus Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 19. Lantheus Recent Developments and Future Plans
   Table 20. Aurobindo Pharma Company Information, Head Office, and Major Competitors
   Table 21. Aurobindo Pharma Major Business
   Table 22. Aurobindo Pharma Targeted Radionuclide Therapy Product and Solutions
   Table 23. Aurobindo Pharma Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 24. Aurobindo Pharma Recent Developments and Future Plans
   Table 25. Mundipharma Company Information, Head Office, and Major Competitors
   Table 26. Mundipharma Major Business
   Table 27. Mundipharma Targeted Radionuclide Therapy Product and Solutions
   Table 28. Mundipharma Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 29. Mundipharma Recent Developments and Future Plans
   Table 30. China Isotope & Radiation Company Information, Head Office, and Major Competitors
   Table 31. China Isotope & Radiation Major Business
   Table 32. China Isotope & Radiation Targeted Radionuclide Therapy Product and Solutions
   Table 33. China Isotope & Radiation Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 34. China Isotope & Radiation Recent Developments and Future Plans
   Table 35. Curium Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 36. Curium Pharmaceuticals Major Business
   Table 37. Curium Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
   Table 38. Curium Pharmaceuticals Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 39. Curium Pharmaceuticals Recent Developments and Future Plans
   Table 40. Gilead Sciences Company Information, Head Office, and Major Competitors
   Table 41. Gilead Sciences Major Business
   Table 42. Gilead Sciences Targeted Radionuclide Therapy Product and Solutions
   Table 43. Gilead Sciences Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 44. Gilead Sciences Recent Developments and Future Plans
   Table 45. Clarity Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 46. Clarity Pharmaceuticals Major Business
   Table 47. Clarity Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
   Table 48. Clarity Pharmaceuticals Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 49. Clarity Pharmaceuticals Recent Developments and Future Plans
   Table 50. Curasight Company Information, Head Office, and Major Competitors
   Table 51. Curasight Major Business
   Table 52. Curasight Targeted Radionuclide Therapy Product and Solutions
   Table 53. Curasight Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 54. Curasight Recent Developments and Future Plans
   Table 55. Nordic Nanovector Company Information, Head Office, and Major Competitors
   Table 56. Nordic Nanovector Major Business
   Table 57. Nordic Nanovector Targeted Radionuclide Therapy Product and Solutions
   Table 58. Nordic Nanovector Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 59. Nordic Nanovector Recent Developments and Future Plans
   Table 60. Philogen Company Information, Head Office, and Major Competitors
   Table 61. Philogen Major Business
   Table 62. Philogen Targeted Radionuclide Therapy Product and Solutions
   Table 63. Philogen Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 64. Philogen Recent Developments and Future Plans
   Table 65. RadioMedix Company Information, Head Office, and Major Competitors
   Table 66. RadioMedix Major Business
   Table 67. RadioMedix Targeted Radionuclide Therapy Product and Solutions
   Table 68. RadioMedix Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 69. RadioMedix Recent Developments and Future Plans
   Table 70. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 71. Telix Pharmaceuticals Major Business
   Table 72. Telix Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
   Table 73. Telix Pharmaceuticals Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 74. Telix Pharmaceuticals Recent Developments and Future Plans
   Table 75. Orano Med Company Information, Head Office, and Major Competitors
   Table 76. Orano Med Major Business
   Table 77. Orano Med Targeted Radionuclide Therapy Product and Solutions
   Table 78. Orano Med Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 79. Orano Med Recent Developments and Future Plans
   Table 80. Actinium Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 81. Actinium Pharmaceuticals Major Business
   Table 82. Actinium Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
   Table 83. Actinium Pharmaceuticals Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 84. Actinium Pharmaceuticals Recent Developments and Future Plans
   Table 85. Y-mAbs Therapeutics Company Information, Head Office, and Major Competitors
   Table 86. Y-mAbs Therapeutics Major Business
   Table 87. Y-mAbs Therapeutics Targeted Radionuclide Therapy Product and Solutions
   Table 88. Y-mAbs Therapeutics Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 89. Y-mAbs Therapeutics Recent Developments and Future Plans
   Table 90. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 91. Fusion Pharmaceuticals Major Business
   Table 92. Fusion Pharmaceuticals Targeted Radionuclide Therapy Product and Solutions
   Table 93. Fusion Pharmaceuticals Targeted Radionuclide Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 94. Fusion Pharmaceuticals Recent Developments and Future Plans
   Table 95. Global Targeted Radionuclide Therapy Revenue (USD Million) by Players (2018-2023)
   Table 96. Global Targeted Radionuclide Therapy Revenue Share by Players (2018-2023)
   Table 97. Breakdown of Targeted Radionuclide Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
   Table 98. Market Position of Players in Targeted Radionuclide Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
   Table 99. Head Office of Key Targeted Radionuclide Therapy Players
   Table 100. Targeted Radionuclide Therapy Market: Company Product Type Footprint
   Table 101. Targeted Radionuclide Therapy Market: Company Product Application Footprint
   Table 102. Targeted Radionuclide Therapy New Market Entrants and Barriers to Market Entry
   Table 103. Targeted Radionuclide Therapy Mergers, Acquisition, Agreements, and Collaborations
   Table 104. Global Targeted Radionuclide Therapy Consumption Value (USD Million) by Type (2018-2023)
   Table 105. Global Targeted Radionuclide Therapy Consumption Value Share by Type (2018-2023)
   Table 106. Global Targeted Radionuclide Therapy Consumption Value Forecast by Type (2024-2029)
   Table 107. Global Targeted Radionuclide Therapy Consumption Value by Application (2018-2023)
   Table 108. Global Targeted Radionuclide Therapy Consumption Value Forecast by Application (2024-2029)
   Table 109. North America Targeted Radionuclide Therapy Consumption Value by Type (2018-2023) & (USD Million)
   Table 110. North America Targeted Radionuclide Therapy Consumption Value by Type (2024-2029) & (USD Million)
   Table 111. North America Targeted Radionuclide Therapy Consumption Value by Application (2018-2023) & (USD Million)
   Table 112. North America Targeted Radionuclide Therapy Consumption Value by Application (2024-2029) & (USD Million)
   Table 113. North America Targeted Radionuclide Therapy Consumption Value by Country (2018-2023) & (USD Million)
   Table 114. North America Targeted Radionuclide Therapy Consumption Value by Country (2024-2029) & (USD Million)
   Table 115. Europe Targeted Radionuclide Therapy Consumption Value by Type (2018-2023) & (USD Million)
   Table 116. Europe Targeted Radionuclide Therapy Consumption Value by Type (2024-2029) & (USD Million)
   Table 117. Europe Targeted Radionuclide Therapy Consumption Value by Application (2018-2023) & (USD Million)
   Table 118. Europe Targeted Radionuclide Therapy Consumption Value by Application (2024-2029) & (USD Million)
   Table 119. Europe Targeted Radionuclide Therapy Consumption Value by Country (2018-2023) & (USD Million)
   Table 120. Europe Targeted Radionuclide Therapy Consumption Value by Country (2024-2029) & (USD Million)
   Table 121. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Type (2018-2023) & (USD Million)
   Table 122. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Type (2024-2029) & (USD Million)
   Table 123. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Application (2018-2023) & (USD Million)
   Table 124. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Application (2024-2029) & (USD Million)
   Table 125. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Region (2018-2023) & (USD Million)
   Table 126. Asia-Pacific Targeted Radionuclide Therapy Consumption Value by Region (2024-2029) & (USD Million)
   Table 127. South America Targeted Radionuclide Therapy Consumption Value by Type (2018-2023) & (USD Million)
   Table 128. South America Targeted Radionuclide Therapy Consumption Value by Type (2024-2029) & (USD Million)
   Table 129. South America Targeted Radionuclide Therapy Consumption Value by Application (2018-2023) & (USD Million)
   Table 130. South America Targeted Radionuclide Therapy Consumption Value by Application (2024-2029) & (USD Million)
   Table 131. South America Targeted Radionuclide Therapy Consumption Value by Country (2018-2023) & (USD Million)
   Table 132. South America Targeted Radionuclide Therapy Consumption Value by Country (2024-2029) & (USD Million)
   Table 133. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Type (2018-2023) & (USD Million)
   Table 134. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Type (2024-2029) & (USD Million)
   Table 135. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Application (2018-2023) & (USD Million)
   Table 136. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Application (2024-2029) & (USD Million)
   Table 137. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Country (2018-2023) & (USD Million)
   Table 138. Middle East & Africa Targeted Radionuclide Therapy Consumption Value by Country (2024-2029) & (USD Million)
   Table 139. Targeted Radionuclide Therapy Raw Material
   Table 140. Key Suppliers of Targeted Radionuclide Therapy Raw Materials

List of Figures

   Figure 1. Targeted Radionuclide Therapy Picture
   Figure 2. Global Targeted Radionuclide Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Targeted Radionuclide Therapy Consumption Value Market Share by Type in 2022
   Figure 4. Beta-emitting
   Figure 5. Targeted Alpha Therapy
   Figure 6. Global Targeted Radionuclide Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 7. Targeted Radionuclide Therapy Consumption Value Market Share by Application in 2022
   Figure 8. Solid Tumor Picture
   Figure 9. Non Hodgkin Lymphoma Picture
   Figure 10. Global Targeted Radionuclide Therapy Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 11. Global Targeted Radionuclide Therapy Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 12. Global Market Targeted Radionuclide Therapy Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
   Figure 13. Global Targeted Radionuclide Therapy Consumption Value Market Share by Region (2018-2029)
   Figure 14. Global Targeted Radionuclide Therapy Consumption Value Market Share by Region in 2022
   Figure 15. North America Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 16. Europe Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 17. Asia-Pacific Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 18. South America Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 19. Middle East and Africa Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 20. Global Targeted Radionuclide Therapy Revenue Share by Players in 2022
   Figure 21. Targeted Radionuclide Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
   Figure 22. Global Top 3 Players Targeted Radionuclide Therapy Market Share in 2022
   Figure 23. Global Top 6 Players Targeted Radionuclide Therapy Market Share in 2022
   Figure 24. Global Targeted Radionuclide Therapy Consumption Value Share by Type (2018-2023)
   Figure 25. Global Targeted Radionuclide Therapy Market Share Forecast by Type (2024-2029)
   Figure 26. Global Targeted Radionuclide Therapy Consumption Value Share by Application (2018-2023)
   Figure 27. Global Targeted Radionuclide Therapy Market Share Forecast by Application (2024-2029)
   Figure 28. North America Targeted Radionuclide Therapy Consumption Value Market Share by Type (2018-2029)
   Figure 29. North America Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2029)
   Figure 30. North America Targeted Radionuclide Therapy Consumption Value Market Share by Country (2018-2029)
   Figure 31. United States Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 32. Canada Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 33. Mexico Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 34. Europe Targeted Radionuclide Therapy Consumption Value Market Share by Type (2018-2029)
   Figure 35. Europe Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2029)
   Figure 36. Europe Targeted Radionuclide Therapy Consumption Value Market Share by Country (2018-2029)
   Figure 37. Germany Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 38. France Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 39. United Kingdom Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 40. Russia Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 41. Italy Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 42. Asia-Pacific Targeted Radionuclide Therapy Consumption Value Market Share by Type (2018-2029)
   Figure 43. Asia-Pacific Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2029)
   Figure 44. Asia-Pacific Targeted Radionuclide Therapy Consumption Value Market Share by Region (2018-2029)
   Figure 45. China Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 46. Japan Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 47. South Korea Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 48. India Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 49. Southeast Asia Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 50. Australia Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 51. South America Targeted Radionuclide Therapy Consumption Value Market Share by Type (2018-2029)
   Figure 52. South America Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2029)
   Figure 53. South America Targeted Radionuclide Therapy Consumption Value Market Share by Country (2018-2029)
   Figure 54. Brazil Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 55. Argentina Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 56. Middle East and Africa Targeted Radionuclide Therapy Consumption Value Market Share by Type (2018-2029)
   Figure 57. Middle East and Africa Targeted Radionuclide Therapy Consumption Value Market Share by Application (2018-2029)
   Figure 58. Middle East and Africa Targeted Radionuclide Therapy Consumption Value Market Share by Country (2018-2029)
   Figure 59. Turkey Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 60. Saudi Arabia Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 61. UAE Targeted Radionuclide Therapy Consumption Value (2018-2029) & (USD Million)
   Figure 62. Targeted Radionuclide Therapy Market Drivers
   Figure 63. Targeted Radionuclide Therapy Market Restraints
   Figure 64. Targeted Radionuclide Therapy Market Trends
   Figure 65. Porters Five Forces Analysis
   Figure 66. Manufacturing Cost Structure Analysis of Targeted Radionuclide Therapy in 2022
   Figure 67. Manufacturing Process Analysis of Targeted Radionuclide Therapy
   Figure 68. Targeted Radionuclide Therapy Industrial Chain
   Figure 69. Methodology
   Figure 70. Research Process and Data Source